A detailed history of Pro Share Advisors LLC transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 16,316 shares of STRO stock, worth $56,453. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,316
Previous 10,943 49.1%
Holding current value
$56,453
Previous $61,000 22.95%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.92 - $5.33 $15,689 - $28,638
5,373 Added 49.1%
16,316 $47,000
Q1 2024

May 08, 2024

BUY
$3.27 - $5.65 $35,783 - $61,827
10,943 New
10,943 $61,000
Q3 2023

Nov 13, 2023

BUY
$3.29 - $4.9 $125 - $186
38 Added 0.32%
11,770 $40,000
Q2 2023

Aug 10, 2023

BUY
$4.25 - $5.88 $5,958 - $8,243
1,402 Added 13.57%
11,732 $54,000
Q1 2023

May 11, 2023

SELL
$4.48 - $8.45 $6,092 - $11,491
-1,360 Reduced 11.63%
10,330 $47,000
Q4 2022

Feb 02, 2023

BUY
$5.41 - $8.08 $63,242 - $94,455
11,690 New
11,690 $94,000
Q2 2022

Aug 01, 2022

SELL
$3.41 - $8.95 $44,087 - $115,714
-12,929 Closed
0 $0
Q1 2022

May 10, 2022

SELL
$7.78 - $15.31 $23,814 - $46,863
-3,061 Reduced 19.14%
12,929 $105,000
Q4 2021

Feb 08, 2022

BUY
$14.25 - $23.53 $8,208 - $13,553
576 Added 3.74%
15,990 $238,000
Q3 2021

Nov 12, 2021

SELL
$16.88 - $22.38 $69,343 - $91,937
-4,108 Reduced 21.04%
15,414 $291,000
Q2 2021

Aug 13, 2021

BUY
$18.03 - $23.82 $83,136 - $109,834
4,611 Added 30.92%
19,522 $363,000
Q1 2021

May 14, 2021

BUY
$20.29 - $27.54 $56,284 - $76,395
2,774 Added 22.86%
14,911 $339,000
Q4 2020

Feb 09, 2021

BUY
$10.16 - $23.98 $123,311 - $291,045
12,137 New
12,137 $263,000

Others Institutions Holding STRO

About SUTRO BIOPHARMA, INC.


  • Ticker STRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,161,500
  • Market Cap $180M
  • Description
  • Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...
More about STRO
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.